Status:
COMPLETED
Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Osteoarthritis
Arthritis, Rheumatoid
Eligibility:
All Genders
15+ years
Brief Summary
The main objective of this PMS study was to monitor and assess the safety of Mobic® intramuscular injection (7.5mg \~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to Mobic...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- diagnosed as osteoarthritis and rheumatoid arthritis
- EXCLUSION CRITERIA:
- Known hypersensitivity to meloxicam
- Cross hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs
- Symptoms of asthma, rhinitis, angioneurotic edema, or urticaria following the administration of aspirin or other NSAIDs
- Active peptic ulceration
- Severe hepatic failure.
- Non-dialysed severe renal insufficiency
- Children and adolescents aged 15 years or less
- Pregnancy or breastfeeding
Exclusion
Key Trial Info
Start Date :
March 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
425 Patients enrolled
Trial Details
Trial ID
NCT00612885
Start Date
March 1 2004
End Date
August 1 2005
Last Update
November 1 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Busan, South Korea
2
Boehringer Ingelheim Investigational Site
Daegu, South Korea
3
Boehringer Ingelheim Investigational Site
Daejeon, South Korea
4
Boehringer Ingelheim Investigational Site
Gangwondo, South Korea